Elucida Oncology, a biotechnology company based on C Dots – ultra-small nanoparticles developed at Cornell that show promise in identifying and fighting cancer – recently secured $44 million in financing, in addition to $28 million raised years ago.
A rendering of the molecular structure of a Cornell dot, which is smaller than 10 nanometers.
C Dots, originally called Cornell dots, were created more than 15 years ago in the lab of Uli Wiesner, the Spencer T. Olin Professor of Engineering in the Department of Materials Science and Engineering. Wiesner has been working to put C Dots to use in the fight against cancer ever since.
As a result of their size, C Dots proved safe and effective for use in human beings as both an imaging and a diagnostic tool in early clinical studies. The new funding will help the company gain regulatory approval as a targeted cancer therapeutic, and to expand its management team and its laboratory capabilities.
anonymousInvesting February 23, 2021 at 12:17 pm00